Loading...
XSTO
HNSA
Market cap185mUSD
Jun 11, Last price  
26.02SEK
1D
-0.69%
1Q
17.95%
Jan 2017
-77.67%
IPO
221.64%
Name

Hansa Biopharma AB

Chart & Performance

D1W1MN
P/E
—
P/S
10.30
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.44%
Rev. gr., 5y
119.48%
Revenues
171m
+27.76%
103,6752,983,7594,448,1861,282,2192,618,8351,727,0174,716,0005,434,0002,579,0003,442,0003,358,0003,364,0006,098,00033,878,000154,525,000134,094,000171,316,000
Net income
-807m
L-3.00%
-2,558,185-15,812,150-18,843,239-24,572,021-16,466,035-17,561,999-29,042,000-66,266,000-111,129,000-176,660,000-247,974,000-360,009,000-420,853,000-548,282,000-611,134,000-831,720,000-806,739,000
CFO
-734m
L-2.88%
-15,576,021-13,792,299-18,093,957-27,139,111-20,633,032-14,865,322-23,623,000-57,799,000-94,563,000-150,105,000-204,560,000-334,775,000-290,274,000-481,168,000-502,733,000-755,654,000-733,922,000
Earnings
Jul 17, 2025

Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
URL
https://www.hansabiopharma.com/
IPO date
Oct 17, 2007
Employees
162
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
171,316
27.76%
134,094
-13.22%
154,525
356.12%
Cost of revenue
803,036
924,967
722,582
Unusual Expense (Income)
NOPBT
(631,720)
(790,873)
(568,057)
NOPBT Margin
Operating Taxes
3,034
908
1,155
Tax Rate
NOPAT
(634,754)
(791,781)
(569,212)
Net income
(806,739)
-3.00%
(831,720)
36.09%
(611,134)
11.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
354,308
396,196
BB yield
-14.38%
-17.92%
Debt
Debt current
7,684
7,503
7,165
Long-term debt
1,085,685
881,130
812,418
Deferred revenue
1
29,500
Other long-term liabilities
63,297
5,297
5,949
Net debt
688,089
156,573
(676,596)
Cash flow
Cash from operating activities
(733,922)
(755,654)
(502,733)
CAPEX
(116)
(284)
(3,331)
Cash from investing activities
(116)
(284)
229,313
Cash from financing activities
405,843
(7,545)
1,117,681
FCF
(625,561)
(783,018)
(559,264)
Balance
Cash
405,280
732,060
1,496,179
Long term investments
Excess cash
396,714
725,355
1,488,453
Stockholders' equity
(3,248,181)
(2,416,040)
Invested Capital
552,989
3,952,370
3,844,731
ROIC
ROCE
EV
Common stock shares outstanding
62,835
52,540
44,924
Price
39.20
49.62%
26.20
-46.77%
49.22
-44.57%
Market cap
2,463,126
78.93%
1,376,550
-37.75%
2,211,159
-44.01%
EV
3,151,215
1,533,123
1,534,563
EBITDA
(631,720)
(771,081)
(556,003)
EV/EBITDA
Interest
187,165
105,520
43,666
Interest/NOPBT